Ur

Œ

Ø

۳

Express Mail Label No.

or use through 10/31/2002. OMB 0651-0032 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ons are required to respond to a collection of information unless it displays a valid OMB control number.

der the Paperwork R	eduction Act o	f 1995, no perso
•		

UTILITY PATENT APPLICATION TRANSMITTAL

16303-008030 Attorney Docket No.

Madden, Thomas D. First Inventor LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THERE Title

Assistant Commissioner for Patents

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b)) APPLICATION ELEMENTS See MPEP chapter 600 concerning design patent application contents. Fee Transmittal Form (e.g., PTO/SB/17)

(Submit an original and a duplicate for fee processing) 2. 🔯 Applicant claims small entity status. See 37 CFR 1.27.

з. 🛛 Specification (Total Pages 39 (preferred arrangement set forth below)

- Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D

- Reference to sequence listing, a table, or a computer program listing appendix

- Background of the Invention - Brief Summary of the Invention

- Brief Description of the Drawings (if filed)

- Detailed Description

- Claim(s)

Signature

- Abstract of the Disclosure

[Total Sheets 7 Drawing(s) (35 U.S.C.113) 4. 🛛 [Total Pages 5. Unsigned Declaration Newly executed (original or copy) b. Copy from a prior application (37 CFR 1.63 (d))

(for a continuation/divisional with Box 18 completed) i. \(\subseteq \text{ DELETION OF INVENTOR(S)}

Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).

6. Application Data Sheet. See 37 CFR 1.76

DDRESS TO	Washington, DC 2023

7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission

EL 769990683 US

(if applicable, all necessary) a. Computer Readable Form (CRF)

b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or

ii.

paper number of pages

Statements verifying identity of above copies ACCOMPANYING APPLICATIONS PARTS

	7.000 7				
9. 🔲 10. 🔲	Assignment Papers (cover sheet & document(s)) 37 C.F.R.§3.73(b)Statement Power of (when there is an assignee) Attorney				
11. 🔲	English Translation Document (if applicable)				
12. 🗌	Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations				
13. 🗔	Preliminary Amendment				
14. 🛚	Return Receipt Postcard (MPEP 503) (Should be specifically itemized)				
15. 🗌	Certified Copy of Priority Document(s) (if foreign priority is claimed)				
16. 🔲	Nonpublication Request under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent				
17. 🔲	Other:				

Date

6/29/01

18. If a CONTINUING APPLICATION, check a	opropriate box, and supply	the requisite information	below and	in a preliminary amendment,			
or in an Application Data Sheet under 37 CFR 1.76:							
☐ Continuation ☐ Divisional	☐ Continuation-in-part	(CIP) of prio	r application	No:/			
Prior application information: Exami	ion Divisional Continuation-in-part (CIP) of prior application No: /						
For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.							
19. CORRESPONDENCE ADDRESS							
☑ Customer Number or Bar Code Label	2039 (Insert Customer No. or Att		or 🗆	Correspondence address below			
Name							
Address							
City	State		Zip Code				
Country	Telephone		Fax				
Name (Print/Type) Eugenia Garro	t Wackowski	Registration No. (Attorne	ey/Agent)	37,330			

timated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any Burden Hour Statement: This plm is estimated to tall comments on the amount of time you are required office, Washington, DC 2023 DD NOT SEND FE implete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 202 SF 1242125 v1

Щ ·M